metastatic melanoma

January 2, 2019January 2, 2019

Yervoy, Local Injection of Candidate Therapy Tilsotolimod Shrink Advanced Melanoma Tumors, Trial Shows

News

A combination of Yervoy (ipilimumab) and Idera Pharmaceuticals’ investigational tilsotolimod reduced tumors in four out of 10 advanced melanoma patients included in a Phase 1/2 trial. Findings from the ILLUMINATE-204 trial (NCT02644967) were presented at the European ... Read more

November 30, 2018November 30, 2018

Tavo Reverses Resistance to PD-1 Inhibitors in Metastatic Melanoma, Phase 2b Trial Suggests

News

A combination of Tavo (tavokinogene telseplasmid/IL-12) and Keytruda (pembrolizumab) was effective at reducing tumors in advanced melanoma patients who had failed prior anti-PD-1 therapies, according to early results of a ... Read more

November 28, 2018

Opdivo Cancer Treatment Safe for HIV Patients on Antiretrovirals, Study Suggests

News

Patients with human immunodeficiency virus (HIV) may safely receive immune checkpoint inhibitors as a cancer treatment, as long as they continue taking antiretroviral therapies, a retrospective study shows. Findings ... Read more

October 31, 2018October 31, 2018

Immunotherapy Particularly Effective Against Aggressive Hereditary Melanoma, Study Reports

News

Patients with hereditary melanoma associated with mutations in the CDKN2A gene respond well to immunotherapy, possible due to an increased mutational load in these tumors, a study suggests. The ... Read more

July 12, 2017

Gene Expression Analysis Helps Determine Sensitivity to Immunotherapies

News

Researchers at Johns Hopkins University have discovered that variations in gene expression levels can provide insight into mechanisms that allow tumors to respond to immunotherapies. The study, “Transcriptional Mechanisms ... Read more

October 20, 2016

Metastatic Melanoma Immunotherapy Combo Shows Promise in Phase 1b/2 Trial

News

The experimental immunotherapy SD-101 combined with the anti-PD-1 agent Keytruda (pembrolizumab) is safe and may be a promising approach for patients with metastatic melanoma, according to data from a Phase 1b/2 ... Read more

October 7, 2016

New and Updated Data from Studies of Opdivo and Yervoy Being Presented at ESMO Congress

News

Bristol-Myers Squibb is presenting new data from numerous studies of its cancer therapies Opdivo (nivolumab) and Yervoy (ipilimumab) at the European Society for Medical Oncology (ESMO) 2016 Congress, with a particular focus on combination ... Read more

June 21, 2016June 21, 2016

NHS Approves Immunotherapy Combination for Metastatic Melanoma

News

Metastatic melanoma patients in England and Wales will be the first in Europe to benefit from the combined immunotherapy regimen of nivolumab (Opdivo) and ipilimumab (Yervoy). The therapy was recently approved by the National Institute for Health and Care Excellence (NICE). ... Read more

May 13, 2016May 13, 2016

Bim Marker May Predict Malignancy’s Response to Immunotherapy

News

Mayo Clinic researchers have found that the protein marker Bim may predict reponse in patients treated with anti-PD-1 immunotherapy. According to a recent study, the team believes measuring the Bim ... Read more

metastatic melanoma

Top 10 Immuno-Oncology Stories of 2018

Yervoy, Local Injection of Candidate Therapy Tilsotolimod Shrink Advanced Melanoma Tumors, Trial Shows

Tavo Reverses Resistance to PD-1 Inhibitors in Metastatic Melanoma, Phase 2b Trial Suggests

Opdivo Cancer Treatment Safe for HIV Patients on Antiretrovirals, Study Suggests

Immunotherapy Particularly Effective Against Aggressive Hereditary Melanoma, Study Reports

Gene Expression Analysis Helps Determine Sensitivity to Immunotherapies

Metastatic Melanoma Immunotherapy Combo Shows Promise in Phase 1b/2 Trial

New and Updated Data from Studies of Opdivo and Yervoy Being Presented at ESMO Congress

NHS Approves Immunotherapy Combination for Metastatic Melanoma

Bim Marker May Predict Malignancy’s Response to Immunotherapy

Pin It on Pinterest